There is a steadily widening range of second-line (2L) and subsequent treatment options for patients with advanced UC including chemotherapy, immune checkpoint inhibitors (ICIs) and novel therapies. In recent years, ICIs have predominantly replaced chemotherapy as the preferred 2L treatment. Furthermore, antibody-drug conjugates (ADC) and targeted agents have become available.

The selection of 2L and salvage treatments for advanced UC depends on many factors, including the initial treatment strategy used in the first-line setting. Molecular classifications appear to be promising in disease prognostication and prediction for UC.

Let's watch the recorded video on 'Frequently Asked Questions (FAQs) for 2L and Salvage Treatments' to gain comprehensive insights from leading experts – Dr. Francisco X. Real from National Cancer Research Center of Spain and Dr. Enrique Grande from MD Anderson Cancer Center Madrid.